home / stock / tcon / tcon news

TCON News and Press, TRACON Pharmaceuticals Inc. From 08/07/19

Stock Information
Company Name: TRACON Pharmaceuticals Inc.
Stock Symbol: TCON
Market: OTC
Website: traconpharma.com
Menu
TCON TCON Quote TCON Short TCON News TCON Articles TCON Message Board
Get TCON Alerts

News, Short Squeeze, Breakout and More Instantly...
TCON - Tracon EPS misses by $0.02

Tracon (NASDAQ: TCON ): Q2 GAAP EPS of -$0.21 misses by $0.02 . More news on: TRACON Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

TCON - TRACON Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pha...

TCON - TRACON Pharmaceuticals to Participate in the 2019 BTIG Biotechnology Conference

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharma...

TCON - Week In Review: United Healthcare, A China Hospital Chain, Acquired For $1.4 Billion

Deals and Financings United Family Healthcare, a chain of nine private China hospitals, agreed to be acquired by New Frontier Corp. (NFC), a public investment vehicle, at an expected value of $1.44 billion. UFH is currently owned by TPG and Fosun Pharma (SHA: 600196; HK: 2196). It is one...
TCON - I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of the CD73 Antibody TJD5 in Patients with Advanced Solid Tumors

SHANGHAI, China and SAN DIEGO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- I-Mab Biopharma (I-Mab), a China and U.S.-based clinical stage biopharmaceutical company exclusively focusing on the discovery and development of potential first-in-class and best-in-class biologics in immuno-oncology and auto...

TCON - TRACON to Report Second Quarter 2019 Company Highlights and Financial Results on August 7, 2019

SAN DIEGO, July 31, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and wet age-related macular degeneration through our license to Santen Pha...

TCON - TRACON Pharmaceuticals to Participate in Wells Fargo Securities 2019 Biotech Corporate Access Day

SAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharma...
TCON - TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer

Phase 1 Data Published in ASCO Proceedings Determined the Recommended Phase 2 Dose Additional Cohort of Patients with a Specific Androgen Receptor Point Mutation Added to Ongoing Phase 2 Study Phase 2 Data Expected in 2 nd half 2020; Potential for $45 Million Opt-in Payment from ...

TCON - TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer

Phase 1 Data Published in ASCO Proceedings Determined the Recommended Phase 2 Dose Additional Cohort of Patients with a Specific Androgen Receptor Point Mutation Added to Ongoing Phase 2 Study Phase 2 Data Expected in 2 nd half 2020; Potential for $45 Million Opt-in Payment from ...

TCON - TRACON Pharmaceuticals to Present at the Jefferies 2019 Healthcare Conference

SAN DIEGO, May 30, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, and through our license to Santen Pharmaceutical Co. Ltd., wet age‐...
Previous 10 Next 10